FTH · Faeth Therapeutics, Inc.
$32.34
+3.79 (+13.27%)
At close · Aug 14
Going-concern doubt
— cleared Aug 4, 2026
The latest filing no longer states the doubt (first flagged May 15, 2026).
View the 10-Q filed Aug 4, 2026Market Cap
$835.68M
Shares
25.84M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$21.09M
+30.1%
FY2025
Diluted EPS
-$16.72
+30.4%
FY2025
Operating Cash Flow
-$20.45M
+17.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $34.02M | $11.33M | $13.04M | $18.77M | $19.81M | $15.82M | $7.53M | |
| — | $122K | $551K | $571K | $614K | $685K | $209K | |
| — | — | — | $200K | — | — | — | |
| $198.82M | $22.29M | $32.61M | $37.06M | $50.19M | $37.48M | $19.45M | |
| -$198.82M | -$22.29M | -$32.61M | -$37.06M | -$50.19M | -$37.48M | -$19.45M | |
| — | $32K | $90K | $144K | $219K | $670K | $1.69M | |
| $138K | -$4000 | -$3000 | -$215K | $36K | -$9000 | — | |
| — | -$21.09M | -$30.16M | — | — | — | — | |
| — | $0 | $0 | — | — | — | — | |
| -$195.53M | -$21.09M | -$30.16M | -$34.1M | -$48.59M | -$36.79M | -$20.1M | |
| -$195.53M | -$21.09M | -$30.16M | -$34.1M | -$48.59M | -$36.79M | -$20.2M | |
| -$195.58M | -$21.07M | -$29.96M | -$33.31M | -$49.26M | -$37.13M | -$20.2M | |
| USD/shares | — | -$16.72 | -$24.01 | -$24.40 | -$31.60 | -$26.60 | — |
| USD/shares | — | -$16.72 | -$24.01 | -$24.40 | -$31.60 | -$26.60 | — |
| shares | — | 1.26M | 1.26M | 1.4M | 1.54M | 1.39M | 80.61K |
| shares | — | 1.26M | 1.26M | 1.4M | 1.54M | 1.39M | 80.61K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.76×
EV/EBIT
—
Peer median 23.46×
P/E (TTM)
—
Peer median 13.53×
Peer medians compare against the 302 similar-size Biotechnology companies (of 545 listed).
Key facts
CIK
1829802
CUSIP
81728A207
13F (30d)
49 filings
47 filers
Visit website
Investor relations